Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.
You may also be interested in...
Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.
Teva Pits Oral Laquinimod Against Avonex In MS Trial
BRAVO trial is the second Phase III study underway for the novel oral drug.
Genentech’s Rituxan Fails Against PPMS
Late-stage lupus trial is still a wild card for anti-B-cell therapy.